Aethlon Medical To Present Bioweapon Treatments At NYSSA Homeland Security Industry Conference

SAN DIEGO, Feb 15, 2005 - Aethlon Medical, Inc. (OTCBB: AEMD) announced today that Company Chairman and CEO, James A. Joyce will present at the NYSSA Homeland Security Industry Conference on March 2nd. Mr. Joyce will update attendees on the development progress of Aethlon's treatment countermeasures against biological weapons, and will also discuss the Company's upcoming trials to treat HIV-Infected individuals in India. The Conference will be held at the Harvard Club in New York City. Additional details can be found at www.nyssa.org.

About The NYSSA

The New York Society of Security Analysts (NYSSA) has educated and inspired investment professionals since 1937, providing them with a unique forum for the exchange of ideas and information. NYSSA's founders included Benjamin Graham, "the father of security analysis" and one of the most influential men in the history of finance. As a not-for-profit educational organization, NYSSA's twin goals are to inform and educate investors; and to advance the professional competence of investment professionals, including security analysts, portfolio managers, investment advisors, and others involved in the investment process.

Conference Background

In October of 2004, President Bush signed the 2005 Homeland Security Appropriations Act, which provides $28.9 billion in discretionary spending for the Department of Homeland Security--$1.8 billion more than the 2004 level and a 6.6% increase over the previous year. A total of $40.7 billion will be available to the department in 2005.

Project BioShield will have an additional $2.5 billion in 2005 for medical countermeasures against weapons of mass destruction, and improved bio-surveillance for biological agents in high-threat cities and high-value targets such as stadiums and transit systems. With overall spending up, many public stocks in the homeland security industry are thriving.

Billions more dollars are being invested to protect the world's homes, food supply, mail service, airlines, data, and people. Some researchers anticipate that the homeland security industry will grow to more than $170 billion in 2006.

About Aethlon Medical

Aethlon Medical is pioneering the development of viral filtration devices to treat HIV/AIDS, Hepatitis-C (HCV), and pathogens that are mass casualty biological warfare candidates. Each treatment application employs the use of a proprietary technology known as the Hemopurifier(TM), which is designed to rapidly reduce the presence of infectious disease and toxins in the body. The Hemopurifier converges the established scientific principals of affinity chromatography and hemodialysis as a means to augment the immune response of clearing viruses and toxins from the blood before cell and organ infection can occur. More information on Aethlon Medical and the Hemopurifier technology is available at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

SOURCE: Aethlon Medical, Inc.

Aethlon Medical, Inc. is a featured Company on www.HomelandDefenseStocks.com, www.investorideas.com/Research/Industries/Biotech.asp and www.AidsStocks.com

For full details, click here: http://www.homelanddefensestocks.com/Companies/AethlonMedical/NewsReleases.asp

Aethlon Medical, Inc.
James A. Joyce, 858.459.7800 x301
jj@aethlonmedical.com
or
Investor Awareness, Inc.
Tony Schor/Kevin Dudley, 847-945-2222
info@investorawareness.com